Skip to main content
. 2022 Nov 26;14(12):2614. doi: 10.3390/pharmaceutics14122614

Figure 2.

Figure 2

The in vivo kinetic characteristics of CCM or CCM@PL in Sprague Dawley rats following intravenous administration. (A) Plasma concentration of CCM or CCM@PL. (B) The area under the concentration-time curve (AUC), (C) clearance (Cl), (D) mean residence time (MRT) of CCM or CCM@PL. Data are presented as the means ± SDs (n = 4). ** p < 0.01, and *** p < 0.001.